Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study

Introduction: Gastrointestinal hemorrhage due to vascular malformations has a negative impact on patients' quality of life and consumes an important quantity of resources. Objective: Analyze the cost-effectiveness of long-active releasing octreotide (OCT-LAR) in the treatment of gastrointestinal haemorrhage secondary to vascular malformations. Material and methods: Retrospective study, including 19 pacients that were treated with mensual injections of OCT-LAR between 2008-2013. The number of blood transfusions, hemoglobin levels, hospital admissions and possible side effects during the year before treatment and the year after the start of the treatment were assessed, and cost-effectiveness was analyzed. Results: After the beginning of the treatment with OCT-LAR, complete response was observed in 7 patients (36.8 %), partial response in 7 patients (36.8 %) and 5 patients (26.3 %) continued to require admissions, blood transfusions and/or endoscopic treatment. We observed significant reduction in the length of admission per year (in days) before and after the start of the treatment (22.79 versus 2.01 days, p < 0.0001) as well as in the number of blood transfusions administered (11.19 versus 2.55 blood transfusions per year, p = 0.002). The mean haemoglobin levels increased from 6.9 g/dl to 10.62 g/dl (p < 0.0001). We observed reduction of costs of 61.5 % between the two periods (from 36,072.35 &#8364; to 13,867.57 &#8364; per patient and year, p = 0.01). No side effects related to treatment were described. Conclusion: In conclusion, OCT-LAR seems to be a cost-efficient and safe pharmacological treatment of gastrointestinal haemorrhage secondary to vascular malformations, mainly in patients in whom endoscopic or surgical treatment is contraindicated.

Saved in:
Bibliographic Details
Main Authors: Klímová,Katerina, Padilla-Suárez,Camilo, Giménez-Manzorro,Álvaro, Pajares-Díaz,José Antonio, Clemente-Ricote,Gerardo, Hernando-Alonso,Ana
Format: Digital revista
Language:English
Published: Sociedad Española de Patología Digestiva 2015
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015000200004
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-01082015000200004
record_format ojs
spelling oai:scielo:S1130-010820150002000042015-07-16Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness studyKlímová,KaterinaPadilla-Suárez,CamiloGiménez-Manzorro,ÁlvaroPajares-Díaz,José AntonioClemente-Ricote,GerardoHernando-Alonso,Ana Octreotide LAR Angiodysplasia Gastrointestinal bleeding Cost-effectiveness Introduction: Gastrointestinal hemorrhage due to vascular malformations has a negative impact on patients' quality of life and consumes an important quantity of resources. Objective: Analyze the cost-effectiveness of long-active releasing octreotide (OCT-LAR) in the treatment of gastrointestinal haemorrhage secondary to vascular malformations. Material and methods: Retrospective study, including 19 pacients that were treated with mensual injections of OCT-LAR between 2008-2013. The number of blood transfusions, hemoglobin levels, hospital admissions and possible side effects during the year before treatment and the year after the start of the treatment were assessed, and cost-effectiveness was analyzed. Results: After the beginning of the treatment with OCT-LAR, complete response was observed in 7 patients (36.8 %), partial response in 7 patients (36.8 %) and 5 patients (26.3 %) continued to require admissions, blood transfusions and/or endoscopic treatment. We observed significant reduction in the length of admission per year (in days) before and after the start of the treatment (22.79 versus 2.01 days, p < 0.0001) as well as in the number of blood transfusions administered (11.19 versus 2.55 blood transfusions per year, p = 0.002). The mean haemoglobin levels increased from 6.9 g/dl to 10.62 g/dl (p < 0.0001). We observed reduction of costs of 61.5 % between the two periods (from 36,072.35 &#8364; to 13,867.57 &#8364; per patient and year, p = 0.01). No side effects related to treatment were described. Conclusion: In conclusion, OCT-LAR seems to be a cost-efficient and safe pharmacological treatment of gastrointestinal haemorrhage secondary to vascular malformations, mainly in patients in whom endoscopic or surgical treatment is contraindicated.Sociedad Española de Patología DigestivaRevista Española de Enfermedades Digestivas v.107 n.2 20152015-02-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015000200004en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Klímová,Katerina
Padilla-Suárez,Camilo
Giménez-Manzorro,Álvaro
Pajares-Díaz,José Antonio
Clemente-Ricote,Gerardo
Hernando-Alonso,Ana
spellingShingle Klímová,Katerina
Padilla-Suárez,Camilo
Giménez-Manzorro,Álvaro
Pajares-Díaz,José Antonio
Clemente-Ricote,Gerardo
Hernando-Alonso,Ana
Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
author_facet Klímová,Katerina
Padilla-Suárez,Camilo
Giménez-Manzorro,Álvaro
Pajares-Díaz,José Antonio
Clemente-Ricote,Gerardo
Hernando-Alonso,Ana
author_sort Klímová,Katerina
title Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
title_short Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
title_full Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
title_fullStr Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
title_full_unstemmed Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
title_sort octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study
description Introduction: Gastrointestinal hemorrhage due to vascular malformations has a negative impact on patients' quality of life and consumes an important quantity of resources. Objective: Analyze the cost-effectiveness of long-active releasing octreotide (OCT-LAR) in the treatment of gastrointestinal haemorrhage secondary to vascular malformations. Material and methods: Retrospective study, including 19 pacients that were treated with mensual injections of OCT-LAR between 2008-2013. The number of blood transfusions, hemoglobin levels, hospital admissions and possible side effects during the year before treatment and the year after the start of the treatment were assessed, and cost-effectiveness was analyzed. Results: After the beginning of the treatment with OCT-LAR, complete response was observed in 7 patients (36.8 %), partial response in 7 patients (36.8 %) and 5 patients (26.3 %) continued to require admissions, blood transfusions and/or endoscopic treatment. We observed significant reduction in the length of admission per year (in days) before and after the start of the treatment (22.79 versus 2.01 days, p < 0.0001) as well as in the number of blood transfusions administered (11.19 versus 2.55 blood transfusions per year, p = 0.002). The mean haemoglobin levels increased from 6.9 g/dl to 10.62 g/dl (p < 0.0001). We observed reduction of costs of 61.5 % between the two periods (from 36,072.35 &#8364; to 13,867.57 &#8364; per patient and year, p = 0.01). No side effects related to treatment were described. Conclusion: In conclusion, OCT-LAR seems to be a cost-efficient and safe pharmacological treatment of gastrointestinal haemorrhage secondary to vascular malformations, mainly in patients in whom endoscopic or surgical treatment is contraindicated.
publisher Sociedad Española de Patología Digestiva
publishDate 2015
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015000200004
work_keys_str_mv AT klimovakaterina octreotidelongactivereleaseinthetreatmentofgastrointestinalbleedingduetovascularmalformationscosteffectivenessstudy
AT padillasuarezcamilo octreotidelongactivereleaseinthetreatmentofgastrointestinalbleedingduetovascularmalformationscosteffectivenessstudy
AT gimenezmanzorroalvaro octreotidelongactivereleaseinthetreatmentofgastrointestinalbleedingduetovascularmalformationscosteffectivenessstudy
AT pajaresdiazjoseantonio octreotidelongactivereleaseinthetreatmentofgastrointestinalbleedingduetovascularmalformationscosteffectivenessstudy
AT clementericotegerardo octreotidelongactivereleaseinthetreatmentofgastrointestinalbleedingduetovascularmalformationscosteffectivenessstudy
AT hernandoalonsoana octreotidelongactivereleaseinthetreatmentofgastrointestinalbleedingduetovascularmalformationscosteffectivenessstudy
_version_ 1755938676863401984